Semaglutide

DRUG INFORMATION

  ADULT
    - • Administer WEGOVY once weekly as an adjunct to diet and increased physical
      activity, on the same day each week, at any time of day, with or without meals
      (2.1). • Inject subcutaneously in the abdomen, thigh or upper arm (2.1). • In
      patients with type 2 diabetes, monitor blood glucose prior to starting and during
      WEGOVY treatment (2.1). • Initiate at 0.25 mg once weekly for 4 weeks.
      Source: US FDA label for semaglutide (WEGOVY), section 'dosage and
      administration', retrieved 2026-08-29
    - Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the
      maintenance dosage (2.2 , 2.3). • The maintenance dosage of WEGOVY in adults is
      either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) . • The maintenance dosage
      of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly
      (2.3).
      Source: US FDA label for semaglutide (WEGOVY), section 'dosage and
      administration', retrieved 2026-08-29
    - The time of day and the injection site can be changed without dose adjustment. 2.2
      Recommended Dosage in Adults Dosage Initiation and Escalation • Initiate WEGOVY
      with a dosage of 0.25 mg injected subcutaneously once weekly.
      Source: US FDA label for semaglutide (WEGOVY), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of WEGOVY as an adjunct to a reduced calorie diet and
      increased physical activity for weight reduction and long-term maintenance have
      been established in pediatric patients aged 12 years and older with obesity.
      Source: US FDA label for semaglutide (WEGOVY), section 'pediatric use', retrieved
      2026-08-29
    - • Administer WEGOVY once weekly as an adjunct to diet and increased physical
      activity, on the same day each week, at any time of day, with or without meals
      (2.1). • Inject subcutaneously in the abdomen, thigh or upper arm (2.1). • In
      patients with type 2 diabetes, monitor blood glucose prior to starting and during
      WEGOVY treatment (2.1). • Initiate at 0.25 mg once weekly for 4 weeks.
      Source: US FDA label for semaglutide (WEGOVY), section 'dosage and
      administration', retrieved 2026-08-29
    - Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the
      maintenance dosage (2.2 , 2.3). • The maintenance dosage of WEGOVY in adults is
      either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) . • The maintenance dosage
      of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly
      (2.3).
      Source: US FDA label for semaglutide (WEGOVY), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Patients aged 75 years and older (WEGOVY-treated and placebo-treated) reported
      more serious adverse reactions overall compared to younger adult patients [see
      Adverse Reactions (6.1) ]. 8.6 Renal Impairment No dose adjustment of WEGOVY is
      recommended for patients with renal impairment.
      Source: US FDA label for semaglutide (WEGOVY), section 'use in specific
      populations', retrieved 2026-08-29
    - In a study in patients with renal impairment, including end-stage renal disease,
      no clinically relevant change in semaglutide pharmacokinetics was observed [see
      Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment No dose adjustment of
      WEGOVY is recommended for patients with hepatic impairment.
      Source: US FDA label for semaglutide (WEGOVY), section 'use in specific
      populations', retrieved 2026-08-29
    - Monitor renal function when initiating or escalating doses of WEGOVY in patients
      reporting severe adverse gastrointestinal reactions or in those with renal
      impairment reporting severe adverse gastrointestinal reactions ( 5.5 ). •
      Hypersensitivity Reactions: Anaphylactic reactions and angioedema have been
      reported postmarketing.
      Source: US FDA label for semaglutide (WEGOVY), section 'warnings and cautions',
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - In a study in patients with renal impairment, including end-stage renal disease,
      no clinically relevant change in semaglutide pharmacokinetics was observed [see
      Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment No dose adjustment of
      WEGOVY is recommended for patients with hepatic impairment.
      Source: US FDA label for semaglutide (WEGOVY), section 'use in specific
      populations', retrieved 2026-08-29
    - In a study in patients with different degrees of hepatic impairment, no clinically
      relevant change in semaglutide pharmacokinetics was observed [see Clinical
      Pharmacology ( 12.3 )] .
      Source: US FDA label for semaglutide (WEGOVY), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY
    - Pregnancy Exposure Registry There will be a pregnancy exposure registry that
      monitors pregnancy outcomes in women exposed to semaglutide during pregnancy.
      Source: US FDA label for semaglutide (WEGOVY), section 'pregnancy', retrieved
      2026-08-29
    - Pregnant women exposed to WEGOVY and healthcare providers are encouraged to
      contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com.
      Source: US FDA label for semaglutide (WEGOVY), section 'pregnancy', retrieved
      2026-08-29
    - Risk Summary Based on animal reproduction studies, there may be potential risks to
      the fetus from exposure to semaglutide during pregnancy.
      Source: US FDA label for semaglutide (WEGOVY), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Pharmacologically mediated marked initial maternal body weight loss and reductions
      in body weight gain and food consumption coincided with an increase in early
      pregnancy losses and led to delivery of slightly smaller offspring at greater than
      or equal to 0.075 mg/kg twice weekly (greater than or equal to 1-time human
      exposure).
      Source: US FDA label for semaglutide (WEGOVY), section 'use in specific
      populations', retrieved 2026-08-29
    - When a drug is present in animal milk, it is likely that the drug will be present
      in human milk ( see Data ) .
      Source: US FDA label for semaglutide (WEGOVY), section 'use in specific
      populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for WEGOVY and any potential adverse effects on
      the breastfed infant from WEGOVY or from the underlying maternal condition.
      Source: US FDA label for semaglutide (WEGOVY), section 'use in specific
      populations', retrieved 2026-08-29